Prescription amphetamines in people with opioid use disorder and co-occurring psychostimulant use disorder initiating buprenorphine: an analysis of treatment retention and overdose risk

BACKGROUND: Attention-deficit and hyperactivity disorder (ADHD) is frequently diagnosed in patients with substance use disorders (SUDs), including opioids. There remains concern about the safety and efficacy of prescription amphetamines (PAs) and their impact on effectiveness of opioid use disorder...

Descripción completa

Detalles Bibliográficos
Autores principales: Tardelli, Vitor, Xu, Kevin Y, Bisaga, Adam, Levin, Frances R, Fidalgo, Thiago M, Grucza, Richard A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Pharmacological Treatments
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387656/
https://www.ncbi.nlm.nih.gov/pubmed/37500184
http://dx.doi.org/10.1136/bmjment-2023-300728

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387656/
https://www.ncbi.nlm.nih.gov/pubmed/37500184
http://dx.doi.org/10.1136/bmjment-2023-300728

Ejemplares similares